Purpose: To evaluate the clinical effect of subgingivally administering Periocline as an auxiliary treatment of chronic periodontitis.
Methods: A randomized, single-blind, self-control study was designed.Following initial therapy ,Periocline was administered into the periodontal pocket of treatment sides at baseline and week 1 to week 4, but the control sides received no drug. For both groups,standard clinical indices including plaque index (PLI), gingival index(GI), probing depth (PD) and response to the ointments were evaluated at baseline week 1,week 4 and week 8. The plaque index and gingival index were analyzed by Wilcoxon' test for each treatment. The probing depth was analyzed by Student's t test.
Results: At the baseline,there was no significant difference in the indexes between the two groups (P>0.05). At 1 week after treatment, both groups showed significant improvement in their examined indexes (P<0.01). At week 1 the PLI was significantly lower in the experimental group than that in the control group; at week 4 and week 8 there was no significant difference between the groups. At 1 week after the treatment, the GI had no significant difference between the two groups (P>0.05); but there was difference 4 weeks and 8 weeks after treatment. At 1 week after treatment, PD was significantly different between the two groups (P<0.05), while at week 4 and week 8, were significant difference between the two groups (P<0.01).
Conclusion: Administration of the local drug delivery system of Periocline ointment as the auxiliary treatment of severe chronic Periodontitis could get good clinical results.
Download full-text PDF |
Source |
---|
Orthop Surg
January 2025
School of Exercise and Health Sciences, Xi'an Physical Education University, Xian, China.
Objective: Patellofemoral pain syndrome (PFPS) is a common knee issue, and hip joint function significantly affects knee health. Gluteus activation exercises are a promising treatment for PFPS. This study aims to investigate the impact of gluteal muscle activation exercises on the muscle involvement and movement patterns of young male patients with PFPS.
View Article and Find Full Text PDFBMJ Open
January 2025
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
Objectives: To assess the therapeutic effects and safety of Tongxie Yaofang (TXYF) granules vs placebo as an alternative treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). We hypothesised that TXYF would improve clinical responses among patients with IBS-D.
Design: A randomised, double-blind, placebo-controlled, phase II, superiority trial.
Lancet Diabetes Endocrinol
January 2025
LIB Therapeutics, Cincinnati, OH, USA. Electronic address:
Background: Lerodalcibep, a small binding anti-PCSK9 protein (adnectin), showed effective LDL cholesterol reduction in heterozygous familial hypercholesterolaemia. We aimed to assess the safety and efficacy of lerodalcibep and evolocumab in a globally diverse homozygous familial hypercholesterolaemia population.
Methods: This phase 3, randomised, open-label, crossover, non-inferiority study consisted of two 24-week treatment periods separated by an 8-week washout.
J Phys Act Health
January 2025
Faculdade de Motricidade Humana, Universidade de Lisboa.
Objectives: The objective of this study was to describe the effects of an extra hour of a structured motor program on the motor competence (MC) of children 6-10 years old..
Design: The need for movement interventions to enhance MC among school-aged children has gained vital importance in the last years, given the negative secular trends reported.
JMIR Ment Health
January 2025
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!